Definitions decide pathways: UK gene therapy rewrite means check your category now
The UK will widen its gene therapy definition to catch synthetic and genome-editing products. Regulatory teams should test their pipelines against the new boundary before the legislation arrives.
The boundary is moving, not the science
Most regulatory attention goes to decisions: approvals, opinions, guidance. The UK's confirmation this week that it will widen the definition of gene therapy medicinal products deserves more attention than it will probably get, because it changes which rulebook a product sits under.
The records are clear on the essentials. Following a consultation, the government will amend the Human Medicines Regulations 2012 so that more synthetic and gene-editing medicines fall under the advanced therapies framework. The MHRA and Northern Ireland's health department will pursue secondary legislation to do it. Support was strong: 83% of the 48 respondents backed the proposals.
My position is that sponsors of synthetic and genome-editing products should treat this as a live classification risk now, not as a legislative curiosity to revisit once the text is published. Classification is the first decision in a development programme. It sets the expectations for quality, clinical design and post-authorisation obligations. A change to the boundary can reach back into programmes that were scoped under a different assumption.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this column is based on
- FDA publishes Q&A guidance on transferring a 510(k) clearance between holders FDA CBER · Thu 19 Nov 2026
- UK confirms plan to widen gene therapy definition to cover synthetic and genome-editing products MHRA · Thu 19 Nov 2026
- MHRA to legislate on revised gene therapy definition after strong consultation support MHRA · Thu 19 Nov 2026
- Allarity secures US patent on twice-daily stenoparib dosing, with protection expected into 2045 Allarity Therapeutics, Inc. · Thu 19 Nov 2026
- FDA approves Infilbray, first treatment for neurological symptoms of Type 3 Gaucher disease FDA · Wed 18 Nov 2026
- Commission publishes minutes of SCHEER working group meeting on brain stimulators European Commission (DG SANTE) · Wed 18 Nov 2026
- MHRA announces AdvanceGxP service for earlier support on advanced manufacturing technologies MHRA · Wed 18 Nov 2026
- MHRA updates London AI regulatory sandbox call with next-stage application details MHRA · Wed 18 Nov 2026
Opinion: this column argues a position. Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Safety judgment belongs apart from the product line, and CBER just said so
FDA's new CBER Safety Council sits outside the product offices. PV leaders should test whether their own safety decisions have the same structural distance from commercial pressure.
EMA's CMV immunoglobulin PSUSA ends in maintenance: what a quiet outcome tells PV teams
EMA has closed its periodic safety review of cytomegalovirus immunoglobulin with the marketing authorisations maintained. What the outcome does and does not tell MAHs is worth spelling out.
Clearmind's Hong Kong PTSD patent application is published, not granted
A published application for psychedelic-derived PTSD compounds signals IP positioning, not clinical or regulatory progress. Trial teams should read it that way.